We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+48.75%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$152M
AUM Growth
–
Cap. Flow
+$126M
Cap. Flow %
82.91%
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$65.7M
2
IFRX icon
InflaRx
IFRX
+$33.9M
3
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$26.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 25.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$80.6M 52.91%
+8,930,237
New +$65.7M
IFRX icon
2
InflaRx
IFRX
$271M
$39.3M 25.79%
+1,876,413
New +$33.9M
MRNS
3
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$32.5M 21.3%
+994,363
New +$26.8M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2017 Portfolio in Review

Q4 2017 is the first quarter with a 13F filing on record for Bain Capital Life Sciences Investors, which disclosed 3 positions worth $152M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Dicerna Pharmaceuticals, Inc.: 8,930,237 shares worth $80.6M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets.

  • Bain Capital Life Sciences Investors's largest Q4 2017 buy was Dicerna Pharmaceuticals, Inc.: 8,930,237 shares worth $80.6M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $152M portfolio in Q4 2017.
  • Bain Capital Life Sciences Investors disclosed 3 positions in Q4 2017, its first 13F filing on record.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2017, filed 14 Feb 2018.